Glycated albumin for glycemic control in t2dm population: A multi-dimensional evaluation

Marcello Ciaccio, Chiara Bellia, Emanuela Foglia, Marcello Ciaccio, Lucrezia Ferrario, Mario Plebani, Luca Falqui, Massimiliano Corsi Romanelli, Mario Plebani, Antonio Ceriello, Fabrizio Schettini, Elena Dozio, Silvana Castaldi, Umberto Valentini, Gianluca Perseghin, Angela Girelli, Federico Bertuzzi, Angelo Avogaro, Martina Zaninotto, Antonio NicolucciGraziella Bonetti

Research output: Contribution to journalArticlepeer-review

3 Citations (Scopus)


Purpose: To investigate the glycated albumin (GA) introduction implications, as an add-on strategy to traditional glycemic control (Hb1Ac and fasting plasma glucose – FPG) instruments, considering insulin-naïve individuals with type 2 diabetes mellitus (T2DM), treated with oral therapies. Methods: A Health Technology Assessment was conducted in Italy, as a multi-dimensional approach useful to validate any innovative technology. The HTA dimensions, derived from the EUnetHTA Core Model, were deployed by means of literature evidence, health economics tools and qualitative questionnaires, filled-in by 15 professionals. Results: Literature stated that the GA introduction could lead to a higher number of individuals achieving therapeutic success after 3 months of therapy (97.0% vs 71.6% without GA). From an economic point of view, considering a projection of 1,955,447 T2DM insulinnaïve individuals, potentially treated with oral therapy, GA introduction would imply fewer individuals requiring a therapy switch (−89.44%), with a 1.06% in costs reduction, on annual basis, thus being also the preferable solution from a cost-effectiveness perspective (costeffectiveness value: 237.74 vs 325.53). According to experts opinions, lower perceptions on GA emerged with regard to equity aspects (0.13 vs 0.72, p-value>0.05), whereas it would improve both individuals (2.17 vs 1.33, p-value=0.000) and caregivers quality of life (1.50 vs 0.83, p-value=0.000). Even if in the short term, GA required additional investments in training courses (−0.80 vs 0.10, p-value = 0.036), in the long run, GA could become the preferable technology (0.30 vs 0.01, p-value=0.018) from an organisational perspective. Conclusion: Adding GA to traditional glycaemic control instruments could improve the clinical pathway of individuals with T2DM, leading to economic and organisational advantages for both hospitals and National Healthcare Systems.
Original languageEnglish
Pages (from-to)453-464
Number of pages12
JournalClinicoEconomics and Outcomes Research
Publication statusPublished - 2021

All Science Journal Classification (ASJC) codes

  • Economics, Econometrics and Finance (miscellaneous)
  • Health Policy


Dive into the research topics of 'Glycated albumin for glycemic control in t2dm population: A multi-dimensional evaluation'. Together they form a unique fingerprint.

Cite this